Total Payments
$4,652
2024 Payments
$543.63
Companies
44
Transactions
123
Medicare Patients
30,445
Medicare Billing
$9.5M
Payment Breakdown by Category
Food & Beverage$2,405 (51.7%)
Research$1,844 (39.6%)
Education$402.84 (8.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,405 | 96 | 51.7% |
| Unspecified | $1,844 | 3 | 39.6% |
| Education | $402.84 | 24 | 8.7% |
Payments by Type
General
$2,808
120 transactions
Research
$1,844
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $1,844 | 3 | $0 (2018) |
| Daiichi Sankyo Inc. | $244.50 | 9 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $225.45 | 7 | $0 (2024) |
| PFIZER INC. | $210.53 | 13 | $0 (2024) |
| Exelixis Inc. | $191.99 | 12 | $0 (2018) |
| Gilead Sciences, Inc. | $174.26 | 4 | $0 (2023) |
| Allergan, Inc. | $166.27 | 7 | $0 (2021) |
| Pharmacyclics LLC, an AbbVie Company | $125.83 | 2 | $0 (2022) |
| Seagen Inc. | $117.01 | 6 | $0 (2023) |
| TESARO, Inc. | $103.15 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $543.63 | 28 | Daiichi Sankyo Inc. ($81.43) |
| 2023 | $345.77 | 18 | PFIZER INC. ($79.02) |
| 2022 | $308.28 | 14 | Pharmacyclics LLC, an AbbVie Company ($105.00) |
| 2021 | $380.83 | 16 | Daiichi Sankyo Inc. ($123.73) |
| 2020 | $309.89 | 15 | Allergan, Inc. ($100.46) |
| 2019 | $307.85 | 6 | Gilead Sciences, Inc. ($124.87) |
| 2018 | $1,738 | 9 | Eli Lilly and Company ($1,588) |
| 2017 | $718.40 | 17 | Eli Lilly and Company ($256.66) |
All Payment Transactions
123 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/18/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $28.96 | General |
| Category: Oncology | ||||||
| 09/10/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.58 | General |
| Category: Oncology | ||||||
| 08/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.94 | General |
| 08/08/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 07/30/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $21.92 | General |
| 07/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $13.36 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: ONCOLOGY | ||||||
| 06/18/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: Oncology | ||||||
| 05/21/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Genetically Defined Disease | ||||||
| 05/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.27 | General |
| 05/07/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: Rare Disease | ||||||
| 05/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: ONCOLOGY | ||||||
| 04/23/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 04/23/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: ONCOLOGY | ||||||
| 04/19/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: Oncology | ||||||
| 04/19/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Oncology | ||||||
| 03/12/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $33.16 | General |
| Category: Oncology | ||||||
| 02/14/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1B OPEN-LABEL - PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING GEMCITABINE AND DOCETAXEL WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA | Eli Lilly and Company | $1,844 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 88 | 7,146 | 173,646 | $7.8M | $2.2M |
| 2022 | 90 | 7,037 | 152,975 | $7.5M | $2.1M |
| 2021 | 97 | 8,089 | 172,365 | $8.4M | $2.6M |
| 2020 | 99 | 8,173 | 192,204 | $8.2M | $2.5M |
Total Patients
30,445
Total Services
691,190
Medicare Billing
$9.5M
Procedure Codes
374
All Medicare Procedures & Services
374 procedure records from CMS Medicare Utilization — Page 13 of 15
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 71260 | Ct scan chest with contrast | Office | 2020 | 183 | 198 | $99,000 | $11,158 | 11.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 73 | 73 | $35,770 | $11,122 | 31.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 425 | 1,413 | $36,738 | $10,803 | 29.4% |
| J9070 | Cyclophosphamide, 100 mg | Office | 2020 | 19 | 410 | $43,050 | $10,564 | 24.5% |
| 96417 | Infusion of different chemotherapy drug or substance into a vein up to 1 hour | Office | 2020 | 128 | 215 | $30,100 | $10,559 | 35.1% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2020 | 69 | 80 | $36,000 | $10,157 | 28.2% |
| 83735 | Magnesium level | Office | 2020 | 401 | 1,370 | $31,510 | $9,032 | 28.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 135 | 173 | $26,815 | $8,734 | 32.6% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2020 | 402 | 1,371 | $28,791 | $8,151 | 28.3% |
| J9025 | Injection, azacitidine, 1 mg | Office | 2020 | 18 | 10,100 | $70,700 | $7,752 | 11.0% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2020 | 44 | 62 | $62,000 | $7,202 | 11.6% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2020 | 12 | 47 | $25,850 | $6,830 | 26.4% |
| 70553 | Mri scan of brain before and after contrast | Office | 2020 | 37 | 41 | $59,696 | $6,483 | 10.9% |
| 84100 | Phosphate level | Office | 2020 | 401 | 1,370 | $21,920 | $6,394 | 29.2% |
| 84550 | Uric acid level, blood | Office | 2020 | 401 | 1,370 | $20,550 | $6,095 | 29.7% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2020 | 27 | 5,550 | $27,750 | $5,365 | 19.3% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2020 | 107 | 237 | $15,405 | $5,329 | 34.6% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2020 | 109 | 1,510 | $84,560 | $5,083 | 6.0% |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 2020 | 11 | 10,440 | $20,880 | $4,448 | 21.3% |
| 85055 | Reticulated (young) platelet measurement | Office | 2020 | 52 | 120 | $10,920 | $4,251 | 38.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 409 | 1,250 | $10,000 | $3,719 | 37.2% |
| 78306 | Bone and/or joint imaging, whole body | Office | 2020 | 14 | 17 | $8,143 | $3,030 | 37.2% |
| 88185 | Flow cytometry technique for dna or cell analysis | Office | 2020 | 12 | 184 | $18,584 | $2,923 | 15.7% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2020 | 53 | 153 | $8,721 | $2,555 | 29.3% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 152 | 258 | $14,706 | $2,544 | 17.3% |
About Dr. Mark Olsen, M.D
Dr. Mark Olsen, M.D is a Hematology & Oncology healthcare provider based in Tulsa, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356382592.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Olsen, M.D has received a total of $4,652 in payments from pharmaceutical and medical device companies, with $543.63 received in 2024. These payments were reported across 123 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($2,405).
As a Medicare-enrolled provider, Olsen has provided services to 30,445 Medicare beneficiaries, totaling 691,190 services with total Medicare billing of $9.5M. Data is available for 4 years (2020–2023), covering 374 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Tulsa, OK
- Active Since 06/09/2006
- Last Updated 05/08/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1356382592
Products in Payments
- OPDIVO (Biological) $208.57
- Cabometyx (Drug) $191.99
- Enhertu (Drug) $151.04
- IBRANCE (Drug) $150.18
- Zydelig (Drug) $124.87
- IMBRUVICA (Drug) $105.00
- VARUBI (Drug) $103.15
- Optune (Device) $101.25
- INJECTAFER (Drug) $93.46
- PADCEV (Biological) $90.02
- XPOVIO (Drug) $82.49
- STRATTICE (Device) $76.31
- ADCETRIS (Biological) $66.16
- ZYTIGA (Drug) $63.99
- LIBTAYO (Biological) $59.80
- INQOVI (Drug) $51.16
- Lenvima (Drug) $45.79
- REBLOZYL (Biological) $41.78
- STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS (Device) $40.41
- BRUKINSA (Drug) $40.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Tulsa
Dr. Edwin Mccreary, M.d, M.D
Hematology & Oncology — Payments: $477,532
Hematology & Oncology $477,532
Dr. Ali Moussa, M.d, M.D
Hematology & Oncology — Payments: $11,003
Hematology & Oncology $11,003
Supriya Koya, Md, MD
Hematology & Oncology — Payments: $6,558
Hematology & Oncology $6,558
Dr. Vicki Baker, M.d, M.D
Hematology & Oncology — Payments: $5,946
Hematology & Oncology $5,946
Dr. Jennifer Trottman, Md, MD
Hematology & Oncology — Payments: $4,488
Hematology & Oncology $4,488
Dr. Kevin Weibel, D.o, D.O
Hematology & Oncology — Payments: $4,174
Hematology & Oncology $4,174